Coronavirus information

Information on the coronavirus pandemic for our patients and visitors.

View coronavirus information

Browse site A – Z

Your views

Your Views

Your feedback is vital to us as we continue to increase the quality of our services.

Your views

You are here:

Date: 28 November 2020

Time: 08:54

MRSA bacteraemia indicator

Percentage of patients who developed MRSA bacteraemia

How is the Trust doing?

Your browser does not support this graph; however, you can still view the statistics in the table below.

Rolling year to date (February 2019 – January 2020) 0.0%
Rolling 3 years (February 2017 – January 2020) 0.0%

Lower percentage indicates better performance.

There have been no cases of MRSA in this group of patients since the indicator began measuring in April 2009.

Why is this indicator important?

Meticillin resistant Staphylococcus aureus (MRSA) is part of a group of bacteria called Staphylococcus aureus and is resistant to common antibiotics. These bacteria are commonly carried on the skin and cause a number of infections. Some of these can be serious such as bloodstream infections (bacteraemia).

MRSA bacteraemia can increase patients' length of stay in hospital, the likelihood of complications and reduce the chances of a successful recovery.

All patients undergoing planned cardiac surgery are routinely screened for MRSA. They are then given treatment prior to surgery if necessary to reduce the risk of developing a bacteraemia.

How do we measure this indicator?

Patients admitted for first-time, isolated coronary artery bypass graft who test positive for MRSA bacteraemia at any time during their stay in hospital.

Related pages

Getting Here

Getting here

Information about travelling to, staying at and getting around the hospital.

Getting to the hospital

Jobs at UHB

Jobs at UHB

A great place to work. Learn why.

Jobs at UHB

We're improving the accessibility of our websites. If you can't access any content or if you would like to request information in another format, please view our accessibility statement.